Claudio Laudani on Comparison of Target and Non-target Vessel Revascularization for Recurrent ACS
Claudio Laudani, Cardiovascular Disease Fellow UNICT, Post-Doc Research Scholar UFHealth JAX, shared on LinkedIn:
”Patients undergoing repeat revascularization for recurrent acute coronary syndrome represent a particularly high-risk population, yet limited data exist on whether outcomes differ between target-vessel and non-target-vessel revascularization.
In our latest study from the CAST Registry, published in Journal of Cardiovascular Medicine, we analyzed 299 patients undergoing repeat PCI for ACS, and compared the long-term outcomes of patients undergoing TVR vs. non-TVR.
Alos, we explored the predictors of long-term adverse events in this high-risk population.
In our study, we found that:
- Patients undergoing repeat PCI for ACS represent a very high risk population, with most of the patients presenting with not at target LDL levels.
- This high thrombotic risk is also reflected in the follow-up event rate, as MACE rates were as high as 37% at 3 years.
- There were no significant differences between TVR and non-TVR, suggesting that recurrent ischemia is the reflection of a systematic high thrombotic burden phenotype rather than local procedure failure.
- Variables of procedural complexity were the main predictors of long-term events, including cardiogenic shock at presentation, longer fluoroscopy time, and LAD involvement.
Overall, our data highlight that patients undergoing repeat PCI require a more aggressive treatment to prevent long-term adverse events.”
Read the full article here.
Article: Long-term outcomes of percutaneous coronary intervention for recurrent events in patients undergoing target-vessel vs. nontarget-vessel revascularization
Authors: Simone Finocchiaro, Maria Sara Mauro, Claudio Laudani, Davide Landolina, Placido Maria Mazzone, Antonino Imbesi, Marco Spagnolo, Antonio Greco, Francesco Nasisi, Davide Capodanno

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines